Alveolar Soft Part Sarcoma in Pediatric and Young Adult Patients: A Report From the Children's Oncology Group Study ARST0332
Pediatric Blood & Cancer · 2026-05 · 73 (5)
DOI: 10.1002/1545-5017.70228 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 16.03.2026. Verfasst von Jacquelyn N Crane und 11 weiteren Autor:innen. Beteiligte Einrichtung: Children's Hospital of Philadelphia, Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, U…. Hauptthemen laut MEDLINE: Sarcoma, Alveolar Soft Part, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: California Institute for Regenerative Medicine INFR4 Alpha Clinic Network Expansion Grant, Penn Medicine Abramson Cancer Center Clinical Scientist Scholar, Alex's Lemonade Stand Fund Center of Excellence in Childhood Cancer Drug Development.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Alveolar soft part sarcoma (ASPS) is a rare soft tissue sarcoma occurring most commonly in adolescence and young adulthood.
Methods
We present the clinical characteristics, treatments, and outcomes of patients with newly diagnosed ASPS enrolled on the Children's Oncology Group study ARST0332. Patients were treated with risk‐adapted therapy, including surgery with or without radiotherapy and ifosfamide and doxorubicin.
Results
Twenty‐four patients with ASPS enrolled on ARST0332 between 2007 and 2012 were analyzed. The majority of primaries were extremity tumors (71%) and > 5 cm (54%). Nearly half (46%) of patients had metastatic disease at diagnosis, all of whom had primary tumors > 5 cm and pulmonary metastases with or without extrapulmonary metastases. Six patients were evaluable for response to neoadjuvant chemoradiotherapy without an objective response. Estimated 5‐year event‐free survival (EFS) and overall survival (OS) were 91% and 100% for low‐risk ( n = 11), 0% and 50% for intermediate‐risk ( n = 2), and 0% and 59% for high‐risk disease ( n = 11), respectively. EFS and OS differed significantly by maximal tumor diameter, presence or absence of metastatic disease, risk group, treatment arm, and upfront primary site resection status.
Conclusions
Patients with low‐risk ASPS (non‐metastatic, grossly resected tumors ≤ 5 cm) had excellent outcomes with surgery with or without radiation on ARST0332. Chemotherapy has been reported to be generally ineffective in ASPS and, indeed, there were no objective responses to neoadjuvant chemoradiotherapy on ARST0332. All patients treated with combination chemoradiotherapy ultimately developed disease progression/relapse. A different therapeutic approach is needed for patients with unresectable or metastatic ASPS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Children's Hospital of Philadelphia, Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Biostatistics, College of Public Health and Health Professions and College of Medicine, Gainesville, Florida, USA.
- Department of Orthopedic Surgery, Nationwide Children's Hospital, Columbus, Ohio, USA.
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California, USA.
- Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
- Department of Population and Public Health Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.
ORCID-Profile: Jacquelyn N Crane, Donald A Barkauskas
Förderung
- California Institute for Regenerative Medicine INFR4 Alpha Clinic Network Expansion Grant
- Penn Medicine Abramson Cancer Center Clinical Scientist Scholar
- Alex's Lemonade Stand Fund Center of Excellence in Childhood Cancer Drug Development
- NCI NIH HHS
- NCATS NIH HHS
- Early Career Clinical Investigator Award
- St. Baldrick's Foundation
- Alex's Lemonade Stand Foundation for Childhood Cancer
Zitieren
APA
Crane, J. N., Xue, W., Qumseya, A., Scharschmidt, T., Tringale, K. R., Nunez, O. L., Hu, J., Barkauskas, D. A., Venkatramani, R., Spunt, S. L., Weiss, A. R., & Federman, N. C. (2026). Alveolar Soft Part Sarcoma in Pediatric and Young Adult Patients: A Report From the Children's Oncology Group Study ARST0332. Pediatric Blood & Cancer, 73(5). https://doi.org/10.1002/1545-5017.70228
Vancouver
Crane JN, Xue W, Qumseya A, Scharschmidt T, Tringale KR, Nunez OL, et al. Alveolar Soft Part Sarcoma in Pediatric and Young Adult Patients: A Report From the Children's Oncology Group Study ARST0332. Pediatric Blood & Cancer. 2026;73(5). doi:10.1002/1545-5017.70228
BibTeX
@article{Crane2026,
author = {Crane, Jacquelyn N and Xue, Wei and Qumseya, Amira and Scharschmidt, Thomas and Tringale, Kathryn R and Nunez, Oscar Lopez and Hu, Jiaqi and Barkauskas, Donald A and Venkatramani, Rajkumar and Spunt, Sheri L and Weiss, Aaron R and Federman, Noah C},
title = {Alveolar Soft Part Sarcoma in Pediatric and Young Adult Patients: A Report From the Children's Oncology Group Study ARST0332},
journal = {Pediatric Blood & Cancer},
year = {2026},
volume = {73},
number = {5},
doi = {10.1002/1545-5017.70228}
}
EUVIMED